Nu-3 Shows High Barrier to Resistance, Aligns with Federal Action Plan
LABT is trading near its 52-week low of $1.66 (13% above the low) on light trading volume (0.2× avg).
Summary
Lakewood-Amedex released new resistance data for its lead candidate Nu-3, showing it does not induce resistance in serial passage experiments and bypasses a wide range of known resistance mechanisms. The data was highlighted in response to the Presidential Advisory Council's National Action Plan on antibiotic resistance, positioning Nu-3 as a potential solution to a critical public health threat. This follows earlier positive data announcements in May and a recent 1-for-10 reverse split to maintain Nasdaq compliance. With a market cap of only $3.3M and a going concern warning, the company remains highly speculative, but the data strengthens the scientific case for its platform. Next steps include advancing Nu-3 into Phase 2 trials for infected diabetic foot ulcers.
At the time of this announcement, LABT was trading at $1.88 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.3M. The 52-week trading range was $1.66 to $98.20. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: PR Newswire.